Bendamustin

Phase 2Small molecule

RRuijin Hospital

Bendamustin is one of 128 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mantle Cell LymphomaActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Follicular LymphomaActive, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 2

Active, not recruiting

Follicular LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

258 competitors in Soft Tissue Sarcoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

34 2

Votrient

Novartis

Phase 3

16 3

Ifex

BBaxter Healthcare Corporation

Phase 3

32 4

Gemzar

Johnson & Johnson

Phase 3

11 5

Yondelis

AApotex Inc.

Phase 3

17 6

Halaven

Eisai

Phase 3

3 7

Neulasta

Amgen

Phase 3

2 8

Ellence

Pfizer

Phase 3

2 9

Taxotere

AAvyxa

Phase 3

10 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Mantle Cell Lymphoma

NCT06136351

Q2 2034

Phase 3Recruiting

Follicular Lymphoma

NCT06284122

Clinical

Trials by Indication[1]

Follicular Lymphoma3 trials

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01216683·289 enrolled

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Unknown status·MMeir Medical Center·Phase 2·NCT04934930·40 enrolled

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT06284122·790 enrolled

Mantle Cell Lymphoma1 trial

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Recruiting·RRuijin Hospital·Phase 2·NCT06136351·23 enrolled

Soft Tissue Sarcoma1 trial

Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT00204620·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Bendamustin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bendamustin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bendamustin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRuijin Hospital

Bendamustin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2034

Trials by Indication[1]

Follicular Lymphoma3 trials

Mantle Cell Lymphoma1 trial

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News